Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HYPD Hyperion DeFi	$7.04 -2.6%	$8.91	$0.85 ▼ $75.18	$40.51M	2.42	825,566 shs	472,836 shs
LIAN LianBio	$0.05 +2.2%	$0.25	$0.27 ▼ $4.99	$5.54M	0.23	1.04 million shs	47,429 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A
THRX Theseus Pharmaceuticals	$4.06	$4.06	$2.05 ▼ $12.37	$179.57M	3.98	592,167 shs	N/A

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HYPD Hyperion DeFi	-2.63%	+29.17%	-41.48%	+523.01%	-88.98%
LIAN LianBio	+2.19%	-6.73%	-87.97%	-74.34%	-84.17%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
THRX Theseus Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HYPD Hyperion DeFi	0.2986 of 5 stars	1.0	0.0	0.0	0.0	2.4	0.8	0.6
LIAN LianBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
THRX Theseus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HYPD Hyperion DeFi	2.00	Hold	$2.00	-71.59% Downside
LIAN LianBio	0.00	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A
THRX Theseus Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HYPD Hyperion DeFi	$67.06K	588.18	N/A	N/A	($695.52) per share	-0.01
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A
THRX Theseus Pharmaceuticals	N/A	N/A	N/A	N/A	$5.36 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HYPD Hyperion DeFi	-$49.82M	-$58.40	N/A	N/A	N/A	-62,238.41%	N/A	-316.90%	N/A
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
PHXM PHAXIAM Therapeutics	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
THRX Theseus Pharmaceuticals	-$50.61M	-$1.34	N/A	N/A	N/A	N/A	-24.84%	-23.64%	N/A

Latest THRX, HYPD, PHXM, and LIAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	HYPD Hyperion DeFi	N/A	-$2.50	N/A	-$2.50	N/A	N/A
5/19/2025	Q1 2025	HYPD Hyperion DeFi	-$7.20	-$1.59	+$5.61	-$1.59	$1.60 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HYPD Hyperion DeFi	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A
THRX Theseus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HYPD Hyperion DeFi	N/A	0.34	0.34
LIAN LianBio	N/A	10.06	10.06
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A
THRX Theseus Pharmaceuticals	N/A	29.93	29.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HYPD Hyperion DeFi	25.84%
LIAN LianBio	74.85%
PHXM PHAXIAM Therapeutics	0.40%
THRX Theseus Pharmaceuticals	91.05%

Insider Ownership

Company	Insider Ownership
HYPD Hyperion DeFi	10.86%
LIAN LianBio	7.59%
PHXM PHAXIAM Therapeutics	1.94%
THRX Theseus Pharmaceuticals	46.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HYPD Hyperion DeFi	40	5.60 million	5.00 million	Optionable
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data
THRX Theseus Pharmaceuticals	38	44.23 million	23.58 million	Optionable

THRX, HYPD, PHXM, and LIAN Headlines

Recent News About These Companies

The True Cost of Layoffs

August 9, 2024 | bloomberg.com

KS2 / KS3 English: A Midsummer Night's Dream. 1: Welcome to Athens

May 20, 2024 | bbc.co.uk

Theseus Pharmaceuticals Announces Closing of Tender Offer

February 14, 2024 | finance.yahoo.com

Theseus Pharmaceuticals Announces Closing of Tender Offer

February 14, 2024 | prnewswire.com

Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals

January 30, 2024 | finance.yahoo.com

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSTR, THRX, GRCL, ROVR

January 20, 2024 | stockhouse.com

Theseus Pharmaceuticals Inc [THRX] Investment Guide: What You Need to Know

January 1, 2024 | knoxdaily.comK

THESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...

December 31, 2023 | businesswire.com

Is Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?

December 29, 2023 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, THRX, CONN

December 27, 2023 | markets.businessinsider.com

Theseus Pharmaceuticals Shares Rise 9.3% on Deal to Be Acquired by Concentra

December 22, 2023 | marketwatch.com

Concentra Biosciences to Acquire Theseus Pharmaceuticals for $3.90 to $4.05/Shr

December 22, 2023 | marketwatch.com

Theseus Pharma To Acquire Concentra Biosciences For $4.05/Shr In Cash

December 22, 2023 | markets.businessinsider.com

THRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to Shareholders

December 22, 2023 | tmcnet.com

Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right

December 22, 2023 | finance.yahoo.com

UP Fintech, Cerence, Irsa Inversiones Y Representaciones among premarket gainers pack

November 27, 2023 | msn.com

Theseus Pharma To Evaluate Expression Of Interest From Foresite, OrbiM And Proposal From Concentra

November 27, 2023 | markets.businessinsider.com

Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC

November 27, 2023 | finance.yahoo.com

Theseus Pharmaceuticals Laying Off 72 Percent of Workforce

November 15, 2023 | precisionmedicineonline.comP

Well-funded Theseus takes bold action for a fresh start

November 15, 2023 | thepharmaletter.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

THRX, HYPD, PHXM, and LIAN Company Descriptions

Hyperion DeFi NASDAQ:HYPD

$7.04 -0.19 (-2.63%)

As of 08/13/2025 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

LianBio NASDAQ:LIAN

$0.05 +0.00 (+2.19%)

As of 08/12/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 08/12/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Theseus Pharmaceuticals NASDAQ:THRX

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time